PERRIGO Co plc (PRGO) stock
PRGONYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 26, 2026Last filing: 10-Q on Nov 4, 2026Score 10/3029% below fair value
$16.24+0.06 (+0.37%)
Close on Nov 13, 2026Market cap $2.25BP/E –Yield 7.14%
Perrigo total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Perrigo's total debt was $3.29B at Sep 26, 2026. For fiscal 2025 it was $3.64B, up 0.6% from the year before. Over ten years it grew 1.3% a year on average. The highest annual figure on record is $6.03B in fiscal 2015.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.64B | +0.6% |
| FY2024 | Dec 31, 2024 | $3.62B | -11.2% |
| FY2023 | Dec 31, 2023 | $4.07B | -0.8% |
| FY2022 | Dec 31, 2022 | $4.11B | +16.6% |
| FY2021 | Dec 31, 2021 | $3.52B | -1.2% |
| FY2020 | Dec 31, 2020 | $3.56B | +5.8% |
| FY2019 | Dec 31, 2019 | $3.37B | +3.9% |
| FY2018 | Dec 31, 2018 | $3.24B | -3.0% |
| FY2017 | Dec 31, 2017 | $3.34B | -44.6% |
| FY2015 | Jun 27, 2015 | $6.03B | +88.0% |
| FY2014 | Jun 28, 2014 | $3.21B | +62.6% |
| FY2013 | Jun 29, 2013 | $1.97B | – |
Quarterly total debt
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Sep 26, 2026 | $3.29B | -9.6% |
| Q2 FY2026CQ2 2026 | Jun 27, 2026 | $3.29B | -9.8% |
| Q1 FY2026CQ1 2026 | Mar 28, 2026 | $3.63B | +0.1% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $3.64B | +0.6% |
| Q3 FY2025CQ3 2025 | Sep 27, 2025 | $3.64B | -23.3% |
| Q2 FY2025CQ2 2025 | Jun 28, 2025 | $3.65B | -10.0% |
| Q1 FY2025CQ1 2025 | Mar 29, 2025 | $3.63B | -10.8% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $3.62B | -11.2% |
| Q3 FY2024CQ3 2024 | Sep 28, 2024 | $4.75B | +16.3% |
| Q2 FY2024CQ2 2024 | Jun 29, 2024 | $4.06B | -0.9% |
| Q1 FY2024CQ1 2024 | Mar 30, 2024 | $4.07B | -0.9% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $4.07B | -0.8% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $4.09B | -0.6% |
| Q2 FY2023CQ2 2023 | Jul 1, 2023 | $4.09B | -0.5% |
| Q1 FY2023CQ1 2023 | Apr 1, 2023 | $4.10B | +16.7% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $4.11B | +16.6% |
| Q3 FY2022CQ3 2022 | Oct 1, 2022 | $4.11B | +15.8% |
| Q2 FY2022CQ2 2022 | Jul 2, 2022 | $4.12B | +15.8% |
| Q1 FY2022CQ1 2022 | Apr 2, 2022 | $3.52B | -1.3% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $3.52B | -1.2% |
| Q3 FY2021CQ3 2021 | Oct 2, 2021 | $3.55B | -0.3% |
| Q2 FY2021CQ2 2021 | Jul 3, 2021 | $3.56B | -14.2% |
| Q1 FY2021CQ1 2021 | Apr 3, 2021 | $3.56B | +2.6% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $3.56B | +5.8% |
| Q3 FY2020CQ3 2020 | Sep 26, 2020 | $3.56B | +5.8% |
| Q2 FY2020CQ2 2020 | Jun 27, 2020 | $4.14B | +18.9% |
| Q1 FY2020CQ1 2020 | Mar 28, 2020 | $3.47B | +7.9% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $3.37B | +3.9% |
| Q3 FY2019CQ3 2019 | Sep 28, 2019 | $3.36B | +3.0% |
| Q2 FY2019CQ2 2019 | Jun 29, 2019 | $3.48B | +6.1% |
| Q1 FY2019CQ1 2019 | Mar 30, 2019 | $3.22B | -3.6% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | $3.24B | -3.0% |
| Q3 FY2018CQ3 2018 | Sep 29, 2018 | $3.27B | -11.6% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $3.28B | -10.7% |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | $3.34B | -42.4% |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | $3.34B | -44.6% |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | $3.69B | – |
| Q2 FY2017CQ2 2017 | Jul 1, 2017 | $3.67B | – |
| Q1 FY2017CQ1 2017 | Apr 1, 2017 | $5.79B | – |
| Q4 FY2015CQ2 2015 | Jun 27, 2015 | $6.03B | – |
See a number that looks wrong?